Age at initial diagnosis and prognosis of breast cancer: a nationwide multicenter retrospective study in China
Huan Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaojia Wang(Hefei University of Technology), Xue-Nong Ouyang, Huawei Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Min Yan(Zhengzhou University), Li Cai(Wenzhou Medical University), Tao Sun(Liaoning Cancer Hospital & Institute), Jianjun He(Sun Yat-sen University), Xinlan Liu(Yunnan Agricultural University), Yongmei Yin(Nanjing Medical University), Yang Shun-e(Xinjiang Medical University), Jiayu Wang(Second Hospital of Shandong University), Hui Li(First Affiliated Hospital of Zhengzhou University), Shusen Wang(Sun Yat-sen University), Hongyuan Li(Central South University), Runxiang Yang(Kunming Medical University), Xichun Hu(Fudan University Shanghai Cancer Center), Tao Huang, Zhongsheng Tong(Tianjin Medical University Cancer Institute and Hospital), Jin‐Hu Fan(Chinese Academy of Medical Sciences & Peking Union Medical College), Quchang Ouyang(Hunan Cancer Hospital), You‐Lin Qiao(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 8
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
LNMAT1 promotes lymphatic metastasis of bladder cancer via CCL2 dependent macrophage recruitment
|Nature Communications|2018|525
Variations in the age‐specific curves of human papillomavirus prevalence in women worldwide
|International Journal of Cancer|2006|417
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417
Targeted therapeutic options and future perspectives for HER2-positive breast cancer
|Signal Transduction and Targeted Therapy|2019|406